My Review for Anti-GATA3 (aa 2-14) polyclonal antibody
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
References
GATA3 expression in the solid cell nest of thyroid
Solid cell nest (SCN) of thyroid is a benign histomorphological mimicker of papillary microcarcinoma. Previous studies have elucidated a few immunohistochemical markers of SCN that aid in its distinction from papillary microcarcinoma. The positivity of GATA3 in SCN has been demonstrated only recently. We also document GATA3 positivity in three cases of SCN.
Biomarkers to diagnose metastatic breast carcinoma to the pancreas: A case report and update
DIAGNOSTIC CYTOPATHOLOGY
Authors: Shee, Kevin; Strait, Alexander M.; Liu, Xiaoying
The patient is a 72-year-old female who presents with new onset jaundice. The patient has a past medical history significant for right-sided estrogen receptor (ER)-positive and left-sided ER-negative breast cancers in 2005 and 2009, respectively, and recent 1-year history of ER-positive right-sided breast cancer with bone and brain metastases. CT scan and endoscopic ultrasound (EUS) revealed a new 2 cm mass in the head of the pancreas, leading to EUS-guided fine-needle aspiration of the lesion. Pathologic workup revealed adenocarcinoma with signet-ring cells, representing either metastatic breast or primary pancreatic cancer. Immunohistochemistry and molecular diagnostic workup identified positive GATA-binding protein 3 (GATA3) immunoreactivity and a mutation in Erb-B2 receptor tyrosine kinase 2 (ERBB2), also known as human epidermal growth factor receptor 2 (HER2). Here, we review the diagnostic markers commonly used to differentiate metastatic breast vs primary pancreatic adenocarcinoma, and discuss the challenges of utilizing GATA3 immunoreactivity and ERBB2 mutations for diagnosis.